South Korean Exporters Face Rising U.S. Trade Barriers
FDA refusals for South Korean food and medical shipments rose 8 percent in the first half of 2025 compared to the previous year.
Updated on Oct. 25, 2026 in International Trade
Live Poll
Do you support the implementation of stricter international trade and labeling regulations on imported goods?
South Korean exporters are navigating an increasingly complex regulatory landscape as U.S. shipment refusals reached 284 cases between January and June 2025. This uptick represents an 8 percent increase over the 263 cases reported during the same period in 2024.
Why it matters
Exporters are grappling with heightened U.S. safety and compliance reviews that now include more frequent documentation requests and potential reclassifications. These regulatory hurdles create significant logistical strain for industries ranging from pharmaceuticals to specialized food production.
FDA shipment refusals totaled 284 cases in the first half of 2025, marking an 8 percent increase over the 263 cases recorded during the same period in 2024. These figures follow a historical peak of 318 total refusals reached in 2023.
The players
Food and Drug Administration
The U.S. federal agency responsible for regulating food, pharmaceuticals, and medical devices to ensure consumer safety.
The details
U.S. customs officials are increasingly utilizing stringent safety documentation requests and Harmonized System code reclassifications to restrict incoming goods. Market analysts project that delays will likely worsen as U.S. authorities tighten origin verification requirements for products utilizing Chinese raw materials.
Timeline
In 2019, FDA shipment refusals totaled 222 cases.
FDA shipment refusals reached a peak of 318 cases in 2023.
Between May 2023 and April 2024, the response center received 154 inquiries regarding trade barriers.
The non-tariff barrier response center began operations in May 2024.
From January to June 2025, FDA shipment refusals totaled 284 cases.
Market Dynamics
This trend mirrors the strategic application of the U.S. Harmonized Tariff Schedule classification standards to regulate trade flows. The increased reliance on these standards highlights how regulatory oversight is being leveraged to reshape international supply chain participation.
Investors with exposure to South Korean bio-pharmaceutical or export-oriented manufacturing firms should monitor potential shifts in trade compliance costs. These regulatory barriers may impact profit margins and operational timelines for companies relying on U.S. distribution channels.
The takeaway
Businesses reliant on trans-Pacific trade should prepare for a future where labeling requirements and origin verification become standard tools for market regulation. Proactive documentation management is essential for mitigating the risk of shipment delays in this tightening trade environment.
Further reading
For broader trends regarding global market access, visit the International Trade section.
Source note: This article includes information reported by Pulse.
Live Poll
Do you support the implementation of stricter international trade and labeling regulations on imported goods?
